In compliance with article 118 "authorization of advertising to the public" of the legislative decree of 24 April 2006, number 219
INDICATIONS
Symptomatic treatment of gastrointestinal meteorism and aerophagia in infants and children.
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the components listed in paragraph 6.1
WARNINGS AND PRECAUTIONS FOR USE
Do not exceed the recommended doses. After a short period of treatment (7 days) without appreciable results, consult your doctor. In case of persistence, worsening of symptoms, or if new symptoms appear or in case of prolonged constipation, treatment should be discontinued and the patient should consult his doctor. Do not use in case of suspected intestinal perforation or ileus. Important information about some excipients: MYLICON contains: • less than 1mmol of sodium (23 mg) per dose (20 drops). It can therefore be considered essentially sodium-free; • 0.6 mg of sodium benzoate per dose (20 drops) equivalent to 0.17 mg/kg for a 3.5 kg newborn and 0.03 mg/kg for a 20 kg child. The increase in bilirubin levels following its detachment from albumin can increase neonatal jaundice which can evolve into kernicterus (deposits of unconjugated bilirubin in the brain tissue); • 0.7025 mg of propylene glycol for each dose (20 drops), equivalent to 1.17 mg/ml. Coadministration with any alcohol dehydrogenase substrate such as ethanol may induce serious adverse effects in neonates. • 0.174 mg of ethanol in each single dose (20 drops) which is equivalent to 0.290 mg/ml. The amount of this medicine is equivalent to less than 0.00435 ml of beer or 0.00174 of wine. This medicine contains a quantity of ethanol that does not produce significant effects.
INTERACTIONS
Taking SIMETICONE and mineral oil (paraffin) laxatives at the same time is not recommended, as the combination of these two products reduces their effectiveness.
SIDE EFFECTS
Side effects observed during treatment in clinical studies and integrated with those collected during post-marketing experience are listed in the table below according to System Organ Class (using MedDRA terminology) and according to the following frequency: Very common ≥ 1/10 Common ≥ 1/100 and < 1/10; Uncommon ≥ 1/1,000 and < 1/100; Rare ≥ 1/10,000 and < 1/1,000; Very rare < 1/10,000
Gastrointestinal disorders
Very rare | Vomiting, diarrhea, abdominal pain, ileus, nausea
Pathologies of the skin and subcutaneous tissue
Very rare | Angioedema Rash
Immune system disorders
rare | hypersensitivity reactions,
Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.








